计算溶液所需的质量、体积或浓度。
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Gemcitabine elaidate (CP-4126) is lipophilic pro-agent of Gemcitabine. Gemcitabine elaidate is converted to Gemcitabine by esterases in order to be phosphorylated. Gemcitabine elaidate exhibits anti-tumor activity.
In Vitro
Gemcitabine elaidate (0.2 nM-1 mM; 72 h) inhibits the growth of gemcitabine sensitive and resistant cells, with IC 50 s of 0.0033, 16.0, 0.0042, 13.0, 0.0015, 0.03, 0.0025, 91, 0.0040, 0.0077, 0.028, and 0.088 μM for L1210/L5, L4A6, BCLO, Bara-C, C26-A, C26-G, A2780, AG6000, THX, LOX, MOLT4 and MOLT4/C8 cells, respectively. Gemcitabine elaidate (0.5 nM-1 μM; 72 h) increases S phase accumulation and dose-dependent cell kill in A549 and WiDR cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: A549 and WiDR cellsConcentration: 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1.0 μM Incubation Time: 72 h Result: Induced a G2/M and S phase accumulation.
In Vivo
Gemcitabine elaidate (25-120 mg/kg; i.p. every 3 days for 5 doses) inhibits the solid tumor xenografts growth of non-small cell lung cancer (EKVX), non-classifiable sarcoma (MHMX), fibrous histiocytoma (TAX II-1), malignant melanoma (THX), prostate cancer (CRL-1435), pancreatic cancer (PANC-1) . Gemcitabine elaidate (10-20 mg/kg; p.o. every 3 days for 5 doses) shows acceptable toxicity and significant antitumor activity in the colon cancer xenograft Co6044 bearing mice . Gemcitabine elaidate (p.o. once daily for 5 doses) shows a favorable toxicity and antitumor activity, while the dose of 15 mg/kg is highly toxic in the human colon cancer xenograft Co6044 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female BALB/c nude (nu/nu) mice (5-8 weeks; 20-27 g) were bearing tumor of EKVX, H-146, MHMX, TAX II-1, OHS, THX, MA-11, CRL-1435, PANC-1 and MiaPaCa-2, respectively Dosage: 25-120 mg/kg Administration: I.p. every 3 days for 5 doses Result: Inhibited the growth of EKVX, MHMX, TAX II-1, THX, CRL-1435 and PANC-1, with T/C values of 7%, 1%, 30%, 7%, 9%, and 12%, respectively.
Form:Solid
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 核苷、核苷酸及其类似物 |
| 类(Class) | 嘧啶核苷 |
| 亚类(Subclass) | 嘧啶2'-脱氧核糖核苷 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 嘧啶2'-脱氧核糖核苷 |
| 其他上位类(Alternative Parents) | 氨基嘧啶及其衍生物 嘧啶酮类 脂肪酸酯 氢化嘧啶 咪唑内酰胺类 氧杂环戊烷 杂芳族化合物 氨基酸及其衍生物 仲醇 羧酸酯 氟醇 氧环化合物 氮杂环化合物 一元羧酸及其衍生物 伯胺 烷基氟化物 羰基化合物 碳氢化合物衍生物 有机氟化物 有机氧化物 |
| 分子骨架(Molecular Framework) | 芳香族杂单环化合物 |
| 取代基(Substituents) | 羟基苯甲酸酯 - 氟化烷基 - 烷基溴化物 - 氨基酸 - 氨基酸或其衍生物 - 氨基吡啶 - 芳香族杂单环化合物 - 氮杂环 - 羰基 - 羧酸衍生物 - 羧酸酰胺 - 脂肪酸酯 - 脂肪酰基 - 氟萘醚 - 卤化烷醇 - 杂芳香族化合物 - 烃衍生物 - 羟吡啶 - 咪唑内酰胺 - 单羧酸或其衍生物 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氟化物 - 有机卤化物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 氧杂环 - 氧杂环丁烷 - 初级胺 - 嘧啶 - 嘧啶-2'-脱氧核糖核苷 - 嘧啶酮 - 醛基 |
| 描述(Description) | 该化合物属于嘧啶-2'-脱氧核糖核苷类有机化合物。这类化合物由嘧啶与核糖连接而成,其核糖分子在2位缺乏羟基。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|